Contact CFFC

Jan

Clinical Trial Alerts – January 2022

Cystic Fibrosis Foundation issued the following clinical trial alerts in January:

January 10, 2022

BALANCE-CF 1: Study of BI 1265162, a mucus clearance drug, in teens and adults with CF

Status: Completed with results

Description: This study evaluated the safety and effectiveness of BI 1265162, a drug intended to improve the clearance of mucus from the lungs.

Age: 12 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 40 to 90%

Number of Visits: 5

Length of Participation: 7 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04059094

Phase 2 study of riociguat in adults with CF

Status: Completed with results

Description: This study evaluated the safety, tolerability, and effectiveness of the oral drug riociguat in adults with CF who have two copies of the F508del mutation and were not receiving CFTR modulator therapy.

Age: 18 Years and Older

Mutation: Two Copies F508del

Fev1% Predicted: 60 to 90%

Number of Visits: 9

Length of Participation: 28 days

ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02170025


Comments are closed.